Datamonitor Healthcare: data analysis and insight, Pink Shee...
Listen to the Pharma Intelligence podcasts on Spotify, Apple Podcasts, Soundcloud and Alexa
As the aging population in the US, UK and Europe increases, cases of multiple have increased as well, bring new therapies and questions about the future of care. This webinar provides a comprehensive look at the disease and treatments including the new launches that are transforming clinical practice, the relative value of multiple myeloma regimens, and the evolution of the multiple myeloma market.
Beginning with the current access levers used by payers and a comparison of US and five major European markets, you’ll learn the key factors in European payers’ assessment of multiple myeloma treatments, the significant changes we are seeing in the US oncology market, and why payers have begun imposing cost-control strategies such as ICER and other value frameworks to evaluate cost-effectiveness.
Datamonitor Healthcare: data analysis and insight
The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit.
Datamonitor Healthcare: data analysis and insight, Biomedtra...
Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: